Trust Signals
Evidence-Graded No Sponsored Claims USP-Referenced Reviewed by FormBlends Medical Team Updated 2026-05-29
Key Takeaways
- Bacteriostatic water for injection (BWFI) contains exactly 0.9% w/v benzyl alcohol per USP; sterile water for injection (SWFI) contains no additives whatsoever.
- USP guidance supports multi-dose vial use of BWFI for up to 28 days refrigerated after first puncture; SWFI offers no such window and should be treated as single-use once the stopper is breached.
- Benzyl alcohol is contraindicated in neonates due to documented gasping syndrome; in adults, the volumes used for subcutaneous injection are well tolerated at approved concentrations.
- Both diluents are essentially unbuffered, meaning solution pH after reconstitution is driven by the compound powder, not the water, which matters for peptide solubility and stability.
- Visual clarity is necessary but not sufficient to confirm sterility. A source with a valid NDC number and USP-compliant certificate of analysis is the only reliable safety check.
Direct Answer: Which Do You Use?
Use bacteriostatic water (BWFI) when you need to draw from the same reconstituted vial over multiple days. Use sterile water (SWFI) only for single-dose use or when benzyl alcohol is explicitly contraindicated for your compound or patient. For most peptide research protocols requiring repeated dosing from one vial, BWFI is the correct choice.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
What Exactly Are Sterile Water and BAC Water?
Sterile water for injection (SWFI) is water that has been purified and sterilized to meet USP monograph standards for endotoxins, sterility, and particulate matter. It contains no dissolved salts, buffers, or preservatives. Because it is hypotonic (essentially zero osmolality), it must not be given intravenously in large volumes directly; it is intended as a vehicle to reconstitute or dilute medications before administration.
Bacteriostatic water for injection (BWFI) meets the same USP sterility and endotoxin standards as SWFI, but contains 0.9% w/v benzyl alcohol as an antimicrobial preservative. The benzyl alcohol concentration is specified in the USP monograph. BWFI is approved for use as a diluent in multi-dose vials because the preservative limits microbial proliferation between doses.
What Does Benzyl Alcohol Actually Do, and What Does It Not Do?
Benzyl alcohol (C7H8O, a simple aromatic alcohol) disrupts microbial cell membranes and inhibits cellular metabolism at the concentrations used in BWFI. The 0.9% concentration is sufficient to create a bacteriostatic environment, meaning it slows or stops bacterial replication rather than achieving sterile kill.
What benzyl alcohol does not do:
- It does not re-sterilize a vial that has been contaminated with a heavy inoculum of bacteria or fungi through poor aseptic technique.
- It does not extend the chemical stability (molecular integrity) of the peptide or drug itself. Those are governed by temperature, pH, light exposure, and the peptide's own sequence chemistry.
- It does not prevent degradation caused by hydrolysis or oxidation of the active compound.
At 0.9%, the amount of benzyl alcohol delivered per subcutaneous injection with a typical 0.1 to 0.5 mL draw is very small (roughly 0.9 to 4.5 mg). The FDA-referenced toxic dose concern in neonates involves cumulative benzyl alcohol exposure well above what adults encounter in research dosing protocols, but the neonatal contraindication is absolute and well established in the medical literature.
Evidence Ledger: What the Science Supports
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| BWFI with 0.9% benzyl alcohol inhibits microbial growth in multi-dose vials | USP monograph, pharmacopeial standards, regulatory approval | Supports use for up to 28 days refrigerated | High |
| Benzyl alcohol causes gasping syndrome in neonates at cumulative toxic doses | Clinical case series and FDA Drug Safety Communication | Confirmed risk; absolute contraindication in newborns | High |
| SWFI is safe for single-dose subcutaneous injection at recommended volumes | Regulatory approval, clinical practice standards | Supports single-dose use | High |
| BWFI is safe for subcutaneous use in adults at typical research peptide volumes | Regulatory approval, clinical pharmacology literature | Supports use; no meaningful adverse signal at standard volumes | Moderate to High |
| Benzyl alcohol causes aggregation or degradation of specific peptides or proteins | Formulation science literature, specific product studies (e.g., some insulin analogues) | Documented for some compounds; not universal | Moderate (compound-dependent) |
| SWFI beyond 24 hours in an opened multi-dose vial is microbiologically unsafe | USP guidelines, infection control literature | Supports discarding after 24 hours | High |
| Peptide chemical stability over 28 days in BWFI at 2 to 8 degrees C | Compound-specific stability studies (highly variable by peptide) | Variable; many peptides degrade meaningfully before 28 days | Low to Moderate (peptide-specific) |
What Most Pages Get Wrong About These Two Diluents
The single most repeated error across medspa blogs and peptide forums is conflating microbiological safety with chemical stability. BWFI's 28-day window is a statement about how long the benzyl alcohol can limit bacterial growth in an intact, properly handled vial. It says nothing about whether your peptide remains at full potency over that same period.
Peptide degradation in aqueous solution is driven by hydrolysis of peptide bonds, oxidation of susceptible residues (methionine, cysteine, tryptophan), and deamidation of asparagine and glutamine residues. These reactions proceed on a timeline dictated by temperature, pH, and the specific amino acid sequence. For some peptides, meaningful degradation occurs well within 28 days at refrigerator temperature. For others, stability data support the full window. Without compound-specific stability data, the 28-day figure gives you a microbiological ceiling, not a potency guarantee.
The second common error is treating "sterile water" from an unlicensed vendor as equivalent to USP-grade SWFI. The words "sterile water" on a label do not confirm the product meets USP endotoxin limits (5 EU/mL for intramuscular or subcutaneous use per USP 161), particulate standards, or validated sterility testing. For any injectable diluent, the source matters as much as the label.
Why the 24-Hour Rule Exists: The Chemistry Behind It
SWFI contains no bacteriostatic agent. Once the rubber stopper of a vial is punctured by a needle, a small risk of microbial introduction exists with every subsequent needle insertion, regardless of technique. At room temperature, common contaminants including Staphylococcus epidermidis and gram-negative organisms can reach clinically significant colony counts within hours in an unpreserved aqueous medium. Refrigeration slows but does not stop this growth.
The 24-hour rule for opened SWFI vials is based on infection control principles rather than a precise kill-curve study for every possible organism. It is a conservative threshold reflecting that the absence of a preservative means there is no chemical barrier between any introduced organism and exponential growth in the vial. Benzyl alcohol at 0.9% in BWFI lowers the rate of that growth to a level that regulatory and pharmacopeial bodies have accepted as controlled over 28 days under refrigeration, assuming reasonable aseptic technique at each draw.
Head-to-Head Comparison Table
| Property | Sterile Water (SWFI) | Bacteriostatic Water (BWFI) | Verdict |
|---|---|---|---|
| Preservative | None | 0.9% benzyl alcohol | BWFI wins for multi-dose |
| Post-open shelf life | 24 hours (discard after) | Up to 28 days refrigerated | BWFI wins |
| Neonatal safety | Safe | Contraindicated | SWFI wins for neonates |
| Peptide/protein compatibility | No additive interference | Possible benzyl alcohol interaction with some compounds | SWFI wins when compatibility unknown |
| pH | 5.0 to 7.0 (unbuffered) | 4.5 to 7.0 (unbuffered) | Tie; both are essentially driven by the active compound |
| Osmolality | Near zero (hypotonic) | Near zero (hypotonic) | Tie; neither is isotonic at standard volumes |
| Cost and availability | Widely available, slightly lower cost | Slightly higher cost; available from compounding pharmacies | Tie for most users |
| Single-dose use case | Appropriate and preferred | Acceptable but unnecessary preservative exposure | SWFI preferred for single-dose |
| Regulatory standing | FDA-approved diluent | FDA-approved diluent | Tie |
How Do Normal Saline and Other Diluents Compare?
Normal saline (0.9% sodium chloride for injection) is the most common alternative diluent in clinical settings. It is isotonic and suitable for IV admixture and dilution. However, its ionic strength and chloride ion content can affect the solubility and aggregation of peptides that are sensitive to salt concentration. For subcutaneous peptide reconstitution, it is not automatically interchangeable with SWFI or BWFI without checking the compound's compatibility data.
Acetic acid solutions (commonly 0.1% or 1% acetic acid) are used to reconstitute certain peptides, particularly those that are poorly soluble at neutral pH. Some growth hormone-releasing peptides and other research compounds dissolve more readily in dilute acid. If a manufacturer or certificate of analysis specifies acetic acid as the diluent, substituting plain water can leave undissolved particulate in the vial.
Bacteriostatic normal saline combines the 0.9% sodium chloride of normal saline with 0.9% benzyl alcohol. It is a fourth option with its own compatibility profile and is not equivalent to BWFI in ionic composition.
Operational Guide: Reconstitution Math, Label Literacy, and Red Flags
Reconstitution Math
The concentration formula is straightforward:
Concentration (mcg/mL) = Peptide amount (mcg) divided by diluent volume added (mL)
Example: A 5 mg (5,000 mcg) vial reconstituted with 2 mL of BWFI yields 2,500 mcg per mL. A 0.1 mL draw delivers 250 mcg. A 0.2 mL draw delivers 500 mcg. Record the volume you added on the vial label immediately, including the date of reconstitution.
Reading the Label and COA
For any injectable diluent, look for these on the label or certificate of analysis:
- NDC number: Confirms the product is registered with the FDA. Unlicensed products lack this.
- "For injection" or "USP" on the label: Indicates the product is held to pharmacopeial standards, not just general lab-grade sterility.
- Benzyl alcohol concentration stated as 0.9% w/v: Anything different raises a formulation question.
- Endotoxin test result on the COA: Should be less than 5 EU/mL for subcutaneous or intramuscular diluents per USP 161.
- Sterility test method and pass statement.
Reconstitution Technique
- Wipe the vial stopper with a 70% isopropyl alcohol swab and allow to dry fully (at least 30 seconds, not just a quick pass).
- Draw the required volume of diluent into a syringe.
- Insert the needle at an angle and inject the diluent slowly down the inside wall of the vial. Do not aim the stream directly at the powder cake, as this can cause foaming and aggregation.
- Gently swirl (do not shake). Shaking introduces shear stress that can cause peptide aggregation, particularly for larger peptides and proteins.
- Inspect visually: the solution should be completely clear and colorless.
- Refrigerate immediately at 2 to 8 degrees C. Label with compound name, concentration, reconstitution date, and diluent used.
Red Flags: Discard Immediately If You See
- Any cloudiness, white haze, or visible particles in the diluent or reconstituted solution.
- Color other than clear and colorless (any yellow, brown, or pink tint).
- Vial past its labeled expiration date.
- A stopper that appears cored or damaged from prior needle insertions.
- Any product where the stopper has been left with a needle in place (compromises the closed system).
- Reconstituted BWFI solution that has been outside refrigeration for an extended period, or any SWFI solution beyond 24 hours post-puncture.
FAQ
What is the difference between sterile water and BAC water?
Sterile water for injection (SWFI) is purified water with no additives. Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative. BWFI allows a multi-dose vial to be used over weeks. SWFI should be used within 24 hours once opened.
Can I use sterile water instead of BAC water for peptides?
Yes, but only if you plan to use the entire vial within 24 hours or freeze single-use aliquots immediately. Using SWFI in a multi-dose vial beyond 24 hours creates a meaningful contamination risk because there is no preservative to inhibit bacterial growth.
How long does bacteriostatic water keep a reconstituted peptide stable?
The 0.9% benzyl alcohol in BWFI inhibits microbial growth for up to 28 days after first puncture when refrigerated at 2 to 8 degrees C, per USP guidance. Peptide chemical stability (degradation of the peptide itself) is a separate question and varies by compound.
Is bacteriostatic water safe for injection?
BWFI is FDA-approved for use as a diluent in adults at recommended volumes. Benzyl alcohol toxicity is a documented concern in neonates (gasping syndrome) and is contraindicated in newborns. In adults, the small volumes used for subcutaneous injection are well tolerated.
What concentration of benzyl alcohol is in bacteriostatic water?
USP-compliant bacteriostatic water for injection contains exactly 0.9% w/v benzyl alcohol. This concentration is the established antimicrobial threshold. Products listing a different concentration may not meet the USP monograph standard.
Does benzyl alcohol affect peptide stability?
Benzyl alcohol can interact with certain peptide bonds and cause aggregation or degradation in some formulations, particularly with proteins like insulin and some growth hormone preparations. For most small peptides used in research settings, published compatibility data are limited, so this remains a relevant caution.
What pH is sterile water vs BAC water?
SWFI has a pH typically between 5.0 and 7.0. BWFI with 0.9% benzyl alcohol typically has a pH of 4.5 to 7.0. Both are essentially unbuffered, meaning your reconstituted solution pH will be driven primarily by the peptide or drug powder itself.
Can I use normal saline instead of sterile water or BAC water?
Normal saline (0.9% NaCl) is isotonic and widely used for dilution and IV admixtures, but the sodium chloride and ionic strength can affect the solubility and aggregation of certain peptides. It is not a drop-in substitute for SWFI or BWFI in subcutaneous reconstitution without checking compatibility.
How do I reconstitute a peptide vial correctly?
Draw the diluent into a syringe, inject it slowly down the inside wall of the vial (not directly onto the powder), then gently swirl. Do not shake. Record the volume added so you can calculate the resulting concentration. For multi-dose use, use BWFI and refrigerate immediately.
Where can I buy bacteriostatic water?
BWFI is available from licensed compounding pharmacies, medical supply distributors, and some online pharmacy sources. Products sold without a pharmacy license or NDC number may not meet USP sterility and endotoxin standards, which is a meaningful safety risk for injectable use.
What does a degraded or contaminated diluent look like?
Both SWFI and BWFI should be completely clear and colorless with no particles. Any cloudiness, visible particles, color change, or unusual odor are grounds to discard the vial. Microbial contamination cannot always be detected visually, which is why sterility compliance at the source matters.
Sources
- United States Pharmacopeia. USP-NF Monograph: Water for Injection; Bacteriostatic Water for Injection. USP 43-NF 38.
- United States Pharmacopeia. USP General Chapter 661: Containers; USP General Chapter 161: Transfusion and Infusion Assemblies.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Benzyl alcohol toxicity in neonates. Originally issued 1982; referenced in current FDA labeling guidance.
- Bhatt DL, et al. (cited practice): CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections. MMWR Recomm Rep. 2011;60(RR-3):1 to 83. (Referenced for multi-dose vial sterility principles.)
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129 to 188. (Foundational reference on peptide and protein degradation in solution.)
- Powell MF. Peptide stability in aqueous parenteral formulations: a review of approved peptide and protein drugs for lessons in formulation development. Pharm Biotechnol. 1996;9:101 to 141.
- Pharmaceutical Compounding Accreditation Board (PCAB) and USP Chapter 797: Pharmaceutical Compounding: Sterile Preparations. (Standards for beyond-use dating of compounded sterile preparations.)
- Trissel LA. Handbook on Injectable Drugs. 18th ed. American Society of Health-System Pharmacists. (Compatibility and stability reference for injectable diluents.)
Footer Disclaimers
Platform: This page is published by FormBlends for informational and educational purposes. FormBlends is not a pharmacy, a medical practice, or a licensed healthcare provider. No information on this page constitutes medical advice, diagnosis, or treatment recommendations.
Research Compound or Compounded Medication: Many peptides discussed in the context of reconstitution on this site are research compounds not approved by the FDA for human use, or compounded medications subject to applicable state and federal pharmacy law. Compliance with local law is the sole responsibility of the user.
Results: Individual outcomes from any peptide, drug, or protocol vary substantially. No outcomes described or implied on this page are guaranteed or typical.
Trademark: FormBlends and the FormBlends logo are trademarks of FormBlends. All third-party product names, drug names, and regulatory body names are the property of their respective owners and are used here for identification purposes only. No endorsement by the USP, FDA, or any pharmaceutical manufacturer is implied.